



S&H Form: (2/01)
Attorney Docket No. 522.1921D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mayumi TOMIKAWA et al.

Application No.: 09/910,071

Group Art Unit: To be Assigned

Filed: July 23, 2001

Examiner: To be Assigned

For: METHOD AND APPARATUS FOR EXTRACTING AND EVALUATING MUTUALLY
SIMILAR PORTIONS IN ONE-DIMENSIONAL SEQUENCES IN MOLECULES AND/OR
THREE-DIMENSIONAL STRUCTURE OF MOLECULES

LETTER SUBMITTING DRAWINGS

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants are herewith submitting Figures 10-12, 23A, 23B, 25, 26, 29, 30, 38A, 38B, 39A, 39B, and 46 to include "SEQ ID NO:" and as amended in the Letter to the Examiner Requesting Approval of Changes to the Drawings filed concurrently herewith.

If any further fees are required in connection with the filing of either of these papers, please charge our Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Date: Feb 19, 2002

By: [Signature]
Gene M. Garner II
Registration No. 34,172

700 11th Street, N.W., Ste. 500
Washington, D.C. 20001
(202) 434-1500



S&H Form: (2/01)
Attorney Docket No. 522.1921D2

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Mayumi TOMIKAWA et al.

Application No.: 09/910,071

Group Art Unit: To be Assigned

Filed: July 23, 2001

Examiner: To be Assigned

For: METHOD AND APPARATUS FOR EXTRACTING AND EVALUATING MUTUALLY
SIMILAR PORTIONS IN ONE-DIMENSIONAL SEQUENCES IN MOLECULES AND/OR
THREE-DIMENSIONAL STRUCTURE OF MOLECULES

**LETTER TO THE EXAMINER
REQUESTING APPROVAL OF CHANGES TO THE DRAWINGS**

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Applicants are submitting herewith amended Figures 10-12, 23A, 23B, 25, 26, 29, 30, 38A, 38B, 39A, 39B, and 46 to include "SEQ ID NO:" and the number of the sequence, as indicated in RED on the attached copies of same.

A Letter Submitting Drawings corresponding to the above-mentioned Figures is filed concurrently herewith.

If any further fees are required in connection with the filing of this paper, please charge our Deposit Account No. 19-3935.

Respectfully submitted,

STAAS & HALSEY LLP

Date: Feb 19, 2002

By: 

Gene M. Garner II

Registration No. 34,172

700 11th Street, N.W., Ste. 500
Washington, D.C. 20001
(202) 434-1500
©2001 Staas & Halsey LLP




UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/910,071	07/23/2001	Mayumi Tomikawa	522.1921D2

CONFIRMATION NO. 2943

FORMALITIES LETTER



OC000000006431734

21171
STAAS & HALSEY LLP
700 11TH STREET, NW
SUITE 500
WASHINGTON, DC 20001

Date Mailed: 08/16/2001



NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to the final rulemaking notice published at 55 FR 18230 (May 1, 1990), and 1114 OG 29 (May 15, 1990). If the effective filing date is on or after July 1, 1998, see the final rulemaking notice published at 63 FR 29620 (June 1, 1998) and 1211 OG 82 (June 23, 1998). If the effective filing date is on or after September 8, 2000, see the final rulemaking notice published in the Federal Register at 65 FR 54604 (September 8, 2000) and 1238 OG 145 (September 19, 2000). Applicant must provide an initial computer readable form (CRF) copy of the "Sequence Listing", an initial paper or compact disc copy of the "Sequence Listing", as well as an amendment directing its entry into the application. Applicant must also provide a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d). If applicant desires the sequence listing in the instant application to be identical with that of another application on file in the U.S. Patent and Trademark Office, such request in accordance with 37 CFR 1.821(e) may be submitted in lieu of a new CRF.

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

Ahmad

Customer Service Center

Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE